Daiichi Sankyo Co. Ltd., of Tokyo, said its European subsidiary would add data on 5,000 new patients to a registry it designed to provide insight into the characteristics and management of atrial fibrillation (AF), with a focus on the prevention of thromboembolic events, such as stroke.